Psoriasis increases the risk of concurrent inflammatory bowel disease: A population-based nationwide study in Korea
Jin Yong Lee1, Sungchan Kang2, Jung Min Bae3, Seong Jin Jo4, Seong-Joon Koh5, Hyun-Sun Park6
1 Public Health Medical Service, SMG-SNU Boramae Medical Center, Seoul, Korea
2 Institute of Health and Environment, Seoul National University, Seoul, Korea
3 Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
4 Department of Dermatology, Seoul National University Hospital, Seoul, Korea
5 Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea
6 Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea
20 Boramae-Ro-5-Gil, Dongjak-Gu, Seoul 07061
Source of Support: None, Conflict of Interest: None
Background: The epidemiology of the association between psoriasis and inflammatory bowel disease is poorly defined and remains controversial.
Aim: To evaluate the prevalence of inflammatory bowel disease in patients with psoriasis compared with the general population.
Methods: We searched the nationwide health claims database between 2011 and 2015 and evaluated the prevalence of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
Results: Prevalence of inflammatory bowel disease, Crohn's disease and ulcerative colitis in patients with psoriasis vs the general population in 2011 were 0.16, 0.05 and 0.12% vs 0.08, 0.03 and 0.06%, respectively, which increased significantly with time between 2011 and 2015. Patients with psoriasis consistently revealed higher standardized prevalence (age and sex adjusted) of inflammatory bowel disease, Crohn's disease and ulcerative colitis compared with the general population. Subgroup analysis revealed the highest risk of prevalent inflammatory bowel disease in patients younger than 19 years (crude odds ratio 5.33, 95% confidence interval 3.74–7.59). Severe psoriasis demonstrated higher odds of inflammatory bowel disease (odds ratio 2.96, 95% confidence interval 2.54–3.45) than mild psoriasis (odds ratio 1.68, 95% confidence interval 1.51–1.88).
Limitations: Limited data for doing adjustment and cross-sectional study design.
Conclusions: Psoriasis patients revealed higher risk of inflammatory bowel disease. In particular, young patients and those with severe psoriasis may require closer monitoring and comprehensive management.